If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- EMA Validates Santhera's Marketing Authorization Application for Puldysa® in Duchenne Muscular Dystrophyon June 24, 2019 at 10:00 pm
Pratteln, Switzerland, June 25, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for ... […]
- UK's MHRA renews EAMS Scientific Opinion for Santhera's Idebenone in Duchenne Muscular Dystrophyon June 23, 2019 at 11:04 pm
Pratteln, Switzerland, June 24, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has renewed for a further year the ... […]
- BLOG: Scout Rob Facca's son Louie to serve as Blackhawks draft runneron June 21, 2019 at 5:21 pm
At the age of two, Louie was diagnosed with Duchenne Muscular Dystrophy - a degenerative disease without a cure that affects the voluntary muscles. It's one that until recently saw very few of those ... […]
- Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophyon June 21, 2019 at 6:45 am
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 21, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved ... […]
- Global Duchenne Muscular Dystrophy (DMD) Market Spotlight 2017-2018 & 2019-2026 - ResearchAndMarkets.comon June 19, 2019 at 4:51 am
Sarepta Should Gain Clean Slate With CBER Review of DMD Gene Therapy ... […]
- New discovery could improve therapies for Duchenne muscular dystrophyon June 16, 2019 at 2:34 am
A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart ... […]
- New Discovery may Lead to Improved Therapies for Duchenne Muscular Dystrophyon June 15, 2019 at 1:56 am
Tiny protein, known as sarcospan could play a significant role in combating heart failure associated with Duchenne muscular dystrophy (DMD), the most common fatal genetic disorder among kids, reports ... […]
- Discovery could lead to improved therapies for Duchenne muscular dystrophyon June 14, 2019 at 12:16 pm
Researchers found that the protein sarcospan can play a major role in combating heart failure in patients with Duchenne muscular dystrophy. A new multi-institution study spearheaded by researchers at ... […]
- Researchers' discovery could lead to improved therapies for duchenne muscular dystrophyon June 14, 2019 at 10:26 am
A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating ... […]
- 'We Need To Move Towards A Cure For Duchenne Muscular Dystrophy'on June 14, 2019 at 6:10 am
Karanveer is excited about going to college next month. Two months ago, the 18-year-old passed the 12th standard CBSE examinations with 94.8 per cent. His successes haven’t come easy as he suffers ... […]
via Bing News